Navigation Links
Mylan Wins Its Amlodipine Case With Pfizer

PITTSBURGH, Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Court of Appeals for the Federal Circuit today granted its motion for a reversal of the district court judgment in its patent infringement litigation with Pfizer concerning amlodipine besylate.

On February 22, 2007, the district court for the Western District of Pennsylvania had ruled in favor of Pfizer and Mylan immediately appealed and has continued to fully expect a reversal of the decision. Mylan was able to launch its amlodipine products following a March 22, 2007 decision by the U.S. Court of Appeals for the Federal Circuit that claims 1-3 of the amlodipine '303 patent were invalid.

Robert J. Coury, Mylan's Vice Chairman and Chief Executive Officer commented: "We are pleased to have prevailed in our amlodipine besylate litigation and the judicial system ultimately confirmed the position that we were the first to assert and have consistently maintained concerning this product for over four years. We are further pleased that our first to market generic amlodipine products have saved patients, corporations, the government and taxpayers hundreds of millions of dollars in healthcare costs."

Amlodipine Besylate Tablets are the generic version of Pfizer's Norvasc(R) Tablets, which had U.S. sales of approximately $2.7 billion for the 12-month period ending Dec. 31, 2006, according to IMS Health.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.


'"/>




Page: 1

Related medicine news :

1. Mylan Announces Final FDA Approval for Fluoxetine Capsules
2. Mylan Announces Tentative FDA Approval for Its ANDA
3. Pfizer unveils anti-smoking drug
4. The Effectiveness Of The Breast Cancer Drug By Pfizer
5. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
6. Erectile Dysfunction Drug Viagra Launched In India By Pfizer
7. Pfizer’s Eraxis Approved By The FD
8. Pfizer Launches Viagra For Lung Disease In UK
9. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
10. Pfizer Commences Its Advertising for Celebrex with All the Warnings
11. FDA Approves Pfizer’s Anti-smoking Dru
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/20/2017)... ... ... “Finn Mouseson”: follows the exciting story of a mouse as the need for ... a journey that will show that friends are to be gathered but home is ... illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s degree in Fine Arts from the ...
(Date:9/20/2017)... ... September 20, 2017 , ... Ron Norman, CEO of Team ... week about the value of senior executives, pointed to a quote from William ... has brought us to the present and will lead us into the future," ...
(Date:9/20/2017)... , ... September 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of ... is the creation of published author, Jeanine Liston, a busy mother of five who used ... “I have been writing this book for over twenty years. It was a way ...
(Date:9/20/2017)... ... ... “They Sang At Her Funeral”: a tale of murder that will bring a ... closets. “They Sang At Her Funeral” is the creation of published author, Annalise Harold, ... children and twelve grandchildren. Before becoming a writer, Annalise had the opportunity to relocate ...
(Date:9/19/2017)... ... 2017 , ... With a series of fundraising events, Fight ... in just a couple of weeks for those affected by Hurricane Harvey. After ... organizers expect to double those initial funds with the “Submit Harvey” online auction ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... -- For nearly two decades, New Life Agency has been committed to providing ... New Life Agency announces a powerful three-way partnership designed to deliver substantial ... ... http://www.schrafts2.com/ ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/6/2017)... 6, 2017  Robert G. Szewc, M.D., is recognized ... in recognition of his contributions to the Medical field.  ... Nephrologist at the practice of Kidney and Hypertension Specialists, ... and hypertension solutions. He has worked in this position ... experience, as well as expertise in kidneys, hypertension, chronic ...
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
Breaking Medicine Technology: